Récepteur sTRAIL - 1 (DR4) humain, ;, réactif, exprimé en E. coli , > = 98% ( SDS - PAGE ), >=98%( HPLC), testé sur la culture cellulaire

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) interacts with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and stimulate cell-death signaling pathway. Mutation of the sTRAIL-R1 gene is associated with the pathogenesis of non-Hodgkin′s lymphoma (NHL). In addition, variation of TRAIL-R1 also increases the risk of susceptibility to prostate cancer (PCa) in North Indian population.

General description

Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) also known as DR4, is encoded by the gene mapped to human chromosome 8p21-22. Recombinant human soluble TRAIL Receptor-1/DR4 is a 22.7kDa protein (216 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain. TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins. TRAIL-R1 contains a cytoplasmic "death domain," which can activate the cell’;s apoptotic machinery. TRAIL Receptor-1/DR4 is activated by binding to either membrane anchored or soluble TRAIL/Apo2L.

Physical form

Lyophilized with no additives.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

MSGTGAAAAT PSKVWGSSAG RIEPRGGGRG ALPTSMGQHG PSARARAGRA PGPRPAREAS PRLRVHKTFK FVVVGVLLQV VPSSAATIKL HDQSIGTQQW EHSPLGELCP PGSHRSERPG ACNRCTEGVG YTNASQQLFA CLPCTACKSD EEERSPCTTT RNTACQCKPG TFRNDNSAEM CRKCSTGCPR GMVKVKDCTP WSDIECVHKE SGNGHN